Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers – Business Wire (press release)
|
Celyad to Host Key Opinion Leader Meeting on CAR–T Therapy for the Treatment of Blood Cancers
Business Wire (press release) Celyad (Paris:CYAD) (Brussels:CYAD) (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader luncheon on the topic of CYAD-01 (CAR–T NKG2D) cell therapy for the … |
